Cytokine News and Research

RSS

Study explains why anti-inflammatory drugs benefit only few people with severe COVID-19

The turning point for people with COVID-19 typically comes in the second week of symptoms. As most people begin to recover, a few others find it increasingly difficult to breathe and wind up in the hospital.

16 Nov 2020

Study reveals key role of IL-33 signaling molecule in parasite infections, other health conditions

De'Broski Herbert has a philosophy that's guided his career researching helminths, or parasitic worms, and their interaction with their hosts' immune systems: "Follow the worm."

15 Nov 2020

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

15 Nov 2020

Arthritis drug may improve COVID-19 survival among elderly patients

A type of arthritis drug may reduce the risk of dying for elderly patients with COVID-19.

15 Nov 2020

Antidepressant may prevent worsening of COVID-19 infection, study suggests

The antidepressant fluvoxamine appears to prevent COVID-19 infections from worsening and may help keep patients out of the hospital, a trial based on research from the University of Virginia School of Medicine suggests.

15 Nov 2020

Dopamine-release mechanisms in the brain may play a major role in SARS-CoV-2 infection

The study, which appeared in the Journal of Taibah University Medical Sciences, shows that the SARS-CoV-2 may behave akin to the CNS pathogenic mechanism of JEV and HIV during the early stages of infection.

15 Nov 2020

Human coronaviruses cause processing body loss

Researchers continue to expand their knowledge of coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. Now, a new study published on the preprint server bioRxiv in November 2020 describes a vital mechanism whereby the novel SARS-CoV-2 pathogen can restrict the human host response. In doing so, the study explores how this novel feature of SARS-CoV-2 works and how it results in a reshaping of the human host's immune response.

11 Nov 2020

Research shows a unique T cell receptor repertoire in MIS-C patients

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv in November 2020, as a response to superantigen activation.

11 Nov 2020

Microbes in the lungs could influence lung cancer progression and prognosis

Bottom Line: Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer.

11 Nov 2020

Scientists are developing new treatment option for lung fibrosis

A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.

11 Nov 2020

How SARS-CoV-2 blocks immune response

An international research team has confirmed the mechanism by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Their article titled, “SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling,” is published in the journal Proceedings of the National Academy of Sciences.

11 Nov 2020

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.

10 Nov 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Daily walnut consumption may reduce the risk of heart disease

Findings from a randomized controlled trial recently published in the Journal of the American College of Cardiology, indicate that people in their 60s and 70s who regularly consume walnuts may have reduced inflammation, a factor associated with a lower risk of heart disease, compared to those who do not eat walnuts.

10 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

Translational study within SARS-CoV-2 infected cells opens up new therapeutic avenues

A recent study published on the preprint server bioRxiv in October 2020 shows what the protein translation process looks like in specific terms. In doing so, the study has provided new insights that might prove helpful in developing new therapies for COVID-19 patients.

9 Nov 2020

Researchers compare rhesus and cynomolgus macaques for SARS-CoV-2 vaccine trials

A team of researchers at the Biomedical Primate Research Centre based in the Netherlands have aimed to determine the effects of the SARS-CoV-2 pathogen on these monkeys and, subsequently, whether they make good animal models for future research in the area.

8 Nov 2020